About

NIPD Genetics is a leading innovative biotechnology company active in the field of developing, engineering, and providing in vitro genetic diagnostic solutions. NIPD Genetics was founded in 2010 to commercialize pioneering research work in the field of genetic diagnostics. NIPD Genetics applies its proprietary genetic and bioinformatic analysis methods to develop novel tests and technologies for prediction, diagnosis and prevention of genetic diseases. NIPD Genetics laboratories are accredited by CAP and certified according to CLIA standards. We provide safe, accurate and reliable in vitro diagnostic testing services internationally.

NIPD Genetics consists of a talented and multidisciplinary team of world-class experts and scientists with knowledge and experience in the fields of business, molecular biology, human genetics, genomics, transcriptomics, methylomics, statistics and bioinformatics. The NIPD Genetics R&D department consists of distinguished scientists from the best universities and research centres in Europe and America. They evaluate new ideas based on patient needs and develop innovative tests, which have clinical impact and improve quality of life. NIPD Genetics is led by an executive team with extensive experience in managing healthcare related organizations. The executive team is advised by a board of directors with several years of experience in raising funds and managing new ventures.

Leadership

  • Phillipos Patsalis

    Prof. Philippos Patsalis

    Founder, Chief Executive Director & Chief Medical Officer

    Distinguished Professor Philippos Patsalis is a world-class geneticist, researcher and successful business entrepreneur, who has been leading public and private sector organizations since 1993. Prof. Patsalis held numerous executive positions and he served on several international scientific and business Boards, Committees and Councils during his 25-year distinguished career. Most notably, he held the presidential-appointed position of Minister of Health of the Republic of Cyprus. During his tenure as a Health Minister and under austere IMF, European Central Bank and European Commission economic measures, Prof. Patsalis implemented major reforms on the national healthcare sector. Among others, he restructured the operations of pharmaceuticals, he initiated the autonomization of public hospitals, and he introduced a new healthcare system.

    He is currently the CEO and CMO of NIPD Genetics Public Company, a company he founded and has been successfully leading since its inception in 2010. NIPD Genetics is an international biotechnology company and a key-player within the competitive non-invasive genetic diagnostics field. Its focus is on developing and providing to the international market innovative technologies and products and it has demonstrated substantial growth.

    Earlier in his career, Prof. Patsalis was for 10 year the founder and director of both The Department of Cytogenetics and Genomics and Translational Genetics and for 8 years the Chief Executive Director of The Cyprus Institute of Neurology and Genetics, the largest and most technologically advanced research institute of Cyprus. During his leadership the Institute achieved tremendous growth and international recognition as a center of excellence. Prof. Patsalis was also the founder of the Akeso Fertility Center Company and the founder of The Cyprus School of Molecular Medicine, an academic school for graduate education for which he served as its first Professor, Provost and Chief Executive Director.

    Prof. Patsalis is an accomplished executive director, researcher and entrepreneur who has been bestowed with more than 30 national and international awards and distinctions for his contribution to science, innovation and business. Namely, the US-State Alumni Award of USA State Department, the National Award for Contribution to Scientific Research by the President of the Republic of Cyprus, and The Silver Medal of the Parliament – the highest honor of distinction by the Parliament of the Republic of Cyprus. He filed multiple patents, contributed to over 10 books, has published more than 130 peer-reviewed scientific papers in prestigious Journals, and has been invited to lecture in over 200 institutions, universities and conferences. He obtained more than 40 competitive research grants for tens of millions, including the very prestigious ERC Advance Grant and raised tens of millions of capital investments from individual and investments funds. He currently holds the titles of Distinguished Professor and Honorary Professor awarded to him by The Cyprus Institute of Neurology and Genetics and other Universities.

    Prof. Patsalis is actively involved with Institutions, Councils and company Boards that play a significant role in shaping and structuring policies in public and private organizations. He is the President of the National Board for Research and Innovation (CY), an elected member of the Board of the European Society of Human Genetics (EU) and a Board member of MANA Products Ltd (USA) among others. Prof. Patsalis is an ardent proponent of responsible scientific and business progress and champions the advancement of research, innovation and entrepreneurship.

    Prof. Philippos Patsalis received his BSc degree from the Aristotelian University of Salonica, Greece and his MA, MPh and PhD degrees from the City University of New York. He underwent specialization and post-doctoral training at Cornel Medical Center, New York University, Memorial Sloan Kettering Cancer Center and Columbia University. He is a Certified and Accredited Laboratory Director in Cytogenetics and Molecular Genetics by the New York Department of Health and by the College of American Pathologists. In addition, he is a Certified High Complexity Laboratory Director by the American Board of Bioanalysis.

  • George Koumbaris_1.jpg

    George Koumbaris

    Chief Scientific Officer

    Dr. Koumbaris joined NIPD Genetics in 2011 as the Head of Research and Development and led the company’s R&D activities. He was appointed Chief Scientific Officer at NIPD Genetics in 2015 and oversees all scientific activities. He is an expert in Genomics, Transcriptomics and Epigenomics, Non-Invasive Diagnostics, and Advanced Genetic Technologies. He is also an inventor and author of numerous peer-reviewed papers published in international scientific journals. His research has been presented at various international scientific meetings. Dr. George Koumbaris received his BSc and MSc degrees from Florida State University and completed his PhD in Molecular Genetics at The Cyprus Institute of Neurology and Genetics where he also served for many years as a researcher in Genetics, Biotechnology and Non-Invasive Prenatal Diagnosis.

  • Nicolas Stephanou_1.jpg

    Nicolas Stephanou

    Chief Commercialization Officer

    Dr. Nicolas Stephanou received his BSc in Biochemistry from SUNY Stony Brook, NY, his PhD in Immunology and Microbiology from Cornell University Weill Medical College and his MBA in Strategy from Cornell University Johnson Business School. He has an extensive knowledge and experience in Molecular Genetics as well as products commercialization. He has worked in the Pharmaceutical industry at key managerial positions acquiring extensive experience in product management, strategic marketing, product development and sales at a global level. His responsibilities involved the promotion of both prescription (Rx) pharmaceuticals and Over The Counter (OTC) medicines. In his latest role, he led a company specializing in international sales and marketing of Food Supplements and Medical Devices. Dr. Stephanou joined NIPD Genetics in 2016 as a Chief Commercialization Officer overseeing the sales expansion and global partnerships.

  • Hari Radhakrishnan

    Hari Radhakrishnan

    Chief Business Development Officer

    Dr. Hari Radhakrishnan joined NIPD Genetics in 2015 to lead the marketing and business development efforts of NIPD Genetics. As Chief Business Development Officer, he is responsible for advising the CEO on business strategy, bringing the new products to market, marketing of the company’s product portfolio, training the company’s and partners’ sales teams, and managing the research and regulatory affairs offices. He also advises the research and development team in developing innovative bioinformatics software for various applications. He has extensive knowledge in the fields of high-performance computing and in business development. As an independent software consultant, he worked with several universities and agencies on the application of super computers to solve complex physics and engineering problems. He obtained his Bachelor of Engineering from IIT Roorkee, India; and PhD in Chemical Engineering from University of Minnesota, USA.

  • Andreas Lambis

    Andreas Lambis

    Chief Production and Information Technology Officer

    Andreas Lambis joined NIPD Genetics in 2015. He specializes in business process automations and business driven development of information technology systems that satisfy the needs of the Technology Transfer platform customers and the company’s internal production and services. He has worked for many years in the private sector as a business consultant in the areas of software development and business integration. Andreas is a member of the PMI and has worked in many medium and large projects in the financial, banking, utilities, education, human resources and health services sectors for both private and public institutions in Europe and the Middle East. Andreas Lambis is an engneer by training, B.Sc. with honors and M.S. in Electrical Engineering from the Pennsylvania State University, with extensive experience in the information technology field.

  • Elena Sakkalou Rouva

    Elena Sakkalou Rouva

    Chief Financial Officer

    Mrs Elena Sakkalou Rouva is a Certified Public Accountant. She holds an MBA from Baruch College, City University of New York and an MSc in Risk Management from New York University. Her professional career was mainly in the financial industry. She has extensive experience in the international business sector in Cyprus. Also, in banking, she worked in one of the biggest banks in Cyprus through various positions in internal audit, risk management and NPL management. The main focus of her work was on the credit portfolio of the bank and involved the analysis of financials, business plans, projections, budgets and corporate structures. She joined NIPD Genetics in December 2018 at the position of the Chief Financial Officer.

  • Evie Mallouri_1.jpg

    Evie Mallouri

    Chief Administrative Officer

    Mrs. Mallouri develops and executes NIPD Genetics HR strategies and activities that foster growth, innovation, and organizational effectiveness. She leads the initiative, NIPD Genetics is an Employer of Choice, fostering a work culture that attracts and retains exceptional talent. Mrs. Mallouri joined the company in 2011 and she has more than 25 years of experience in administrative and HR services. Part of her date to date operations include, collaborating with key team members across departments to drive employee engagement, morale and performance and advising the executive team on organizational restructuring so as to create a more agile, cost-efficient workforce. She is also responsible for the negotiation of employees’ and consultants’ contracts and maintaining the company’s archives. Mrs. Mallouri administers the company’s archives and keeps registry of all intellectual property and signed agreements. Additionally, she is responsible for the administration of the Company’s Shareholders activities and keeping a record of the minutes of the Board of Directors. Mrs. Mallouri studied Business Administration and has an M.B.A. from Keele University in the United Kingdom.

  • Marios Ioannides

    Marios Ioannides

    Head of Research and Development

    Dr. Ioannides joined NIPD Genetics in 2015 and is currently the Head of R & D overseeing product development, technology optimization and all research activities of the company. He served for many years as a molecular cytogeneticist, a researcher, and later as acting head of the Translational Gentetics Team at the Cyprus Institute of Neurology and Genetics.He has extensive theoretical and technical knowledge of molecular techniques such as digital PCR and Next Generation Sequencing, as well as of development of clinical tests and clinical diagnostics. He is an expert in genomics, epigenetics and non-invasive diagnostics. He has published several peer-reviewed articles and his research has been presented at various national and international scientific conferences. Dr. Marios Ioannides received his BSc and Msc in Microbiology from the University of South Florida, and his PhD in Medical Genetics from the University of Cyprus and the Cyprus Institute of Neurology and Genetics.

  • Elena Kypri_1.jpg

    Elena Kypri

    Head of Clinical Services

    Dr Kypri joined NIPD Genetics in 2011 and is currently the Head of laboratory operations overseeing all laboratory activities related to the provision of services. She received numerous awards and fellowships and has a broad research background including more than 10 years in molecular and cell biology techniques. She has published several peer-reviewed articles and her research has been presented at various national and international scientific conferences. Dr. Elena Kypri received her Bsc in Clinical Laboratory Science from the University of Arizona and her PhD degree in Molecular Genetics and Microbiology from the University of Texas at Austin. She is also board certified by the American Society of Clinical Pathologists. She underwent specialization and post-doctoral training from the Department of Biological Sciences at University of Cyprus and the Institute of Molecular Biology and Biotechnology in Crete.

Board of Directors

  • Nicos Michaelas

    Nicos Michaelas

    Chairman

    Dr Nicos Michaelas is the Managing Director of Demetra Investments Public Ltd, the largest investment company listed on the Cyprus Stock Exchange. He oversees the operations and the investment portfolio of the company and manages investments across multiple asset classes including capital markets, real estate and private equity. Dr Michaelas is also as Member of the Board of Directors of Logicom Public Ltd, a global IT distribution and services company. Nicos holds a BA(Hons) in Industrial Economics from the University of Nottingham in the UK and a Ph.D. in Financial Economics from Manchester Business School. In his early career he worked as an academic in the UK, researching/teaching business economics and financial management at Manchester Business School. Since the year 2000 he has been working in the investment management industry.

  • Dinos Iordanou photo.jpg

    Constantinos Iordanou

    Vice-Chairman

    Constantine Iordanou has been Chairman of the Board of ACGL since November 2009 and was Chief Executive Officer of ACGL from August 2003 to March 2018. From March 1992 through December 2001, Mr. Iordanou served in various capacities for Zurich Financial Services and its affiliates, including as Senior Executive Vice President of group operations and business development of Zurich Financial Services, President of Zurich-American Specialties Division, Chief Operating Officer and Chief Executive Officer of Zurich-American and Chief Executive Officer of Zurich North America. Prior to joining Zurich, he served as President of the commercial casualty division of the Berkshire Hathaway Group and served as Senior Vice President with the American Home Insurance Company, a member of the American International Group. Since 2001, Mr. Iordanou has served as a director of Verisk Analytics, Inc. (formerly known as ISO Inc.). He holds an aerospace engineering degree from New York University.

  • Phillipos Patsalis

    Prof. Philippos Patsalis

    CEO/Director

    Prof. Philippos Patsalis obtained his BSc in Biology from the Aristotelian University of Salonica, Greece and his MA, MPh and PhD in Genetics from the City University of New York, USA. He underwent specialization and post-doctoral training at Institute Pasteur, France, Cornell Medical Center, New York University, Memorial-Sloan Kettering Cancer Center and Columbia University, in New York, USA. He also received professional certification and licensing to practice as a Laboratory Director in the specialties of Cytogenetics and Molecular Genetics from the New York Department of Health, USA and Accreditation as Laboratory Director in Cytogenetics and Molecular Genetics from College of American Pathologists, USA.

    Prof Patsalis worked as Director and Founder of the Department of Cytogenetics and Genomics and the Translational Genetics Team at the Cyprus Institute of Neurology and Genetics; Founder and Chief Executive Director of the biotechnology company NIPD Genetics; Founder, Professor and Provost of the Cyprus School of Molecular Medicine; Chief Executive Medical Director of the Cyprus Institute of Neurology and Genetics and Minister of Health of the Republic of Cyprus. As of November 2015 he holds the position of Distinguished Professor at the Cyprus Institute of Neurology and Genetics and the Cyprus School of Molecular Medicine and the position of Chief Executive Director of NIPD Genetics. He is also an Honorary Professor of St. George’s University of London/Medical School at the University of Nicosia, Adjunct Professor at the University of Cyprus/Department of Biology and Visiting Professor at the University of Ioannina/Medical School. As of 2010, he serves as Founder and CEO of NIPD Genetics until today, excepting the period that he served as Minister of Health.
    Prof. Patsalis is a scientist with international recognition in the field of Human Genetics. He has been invited as lecturer to more than 200 Universities and international conferences. He has competitively obtained more than 40 research grants and funding of over 20 million euro from international organizations such as the 5th, 6th, 7th European Framework Programs and the most prestigious grant in the European Union known as the ERC Advanced Grant, which is based purely on excellence. He was appointed to several Editorial Boards of scientific journals and has filed several patents. He contributed chapters in 10 books and published more than 130 peer-reviewed scientific publications in international journals, such as Nature Medicine, Lancet, Human Molecular Genetics, American Journal Human Genetics, etc. In Cyprus, he is the President of the National Council of Research, Innovation and Entrepreneurship and has served on several other Boards, Committees and Councils. In Europe, he is the national representative of Cyprus in many European committees and councils, as well as elected Boards of Directors such as the European Society of Human Genetics, the European Cytogenetics Association, etc. He has been appointed as external member of National Academies of Sciences and has been honored with many national and international awards, including the Cyprus National Research Award, the Cyprus National Innovation Award, the Most Notable Scientific and Social Contribution Award University of Nicosia, the US State Alumni Award-State Department USA, the Silver Medal of the Parliament which is the highest honorary distinction of the Parliament of the Republic of Cyprus and the National Award from the President of the Republic of Cyprus.

  • Gregoris Gregoriou

    Gregoris Gregoriou

    Director

    Gregoris Gregoriou, Managing Director, Bunkernet. Has over 25 years of experience in the shipping sector, particularly in the fields of chartering, sales & purchasing and bunkering. He holds a BA in Economics from the University of Kent at Canterbury, and MBA in Finance from Nottingham University and an MSc in Shipping Trade and Finance from the City University, Business School. Throughout his career in the shipping industry he has set up a number of successful companies including One Net in 1997, specializing in integrated solutions of comprehensive satellite communications and marine equipment as well as Bunkernet in 2007, an internationally recognised provider of bunker and lubricant solutions. He is also an active Director of the Fameline Holding Group. Furthermore he is also involved in ongoing projects aimed to address 2020 sulfur cap and emission concerns with the development of physical marine LNG distribution points in North Europe and the East Med.

  • Constantinos Ellinas

    Constantinos Ellinas

    Alternate Director for Gregoris Gregoriou

    Constantinos joined Fameline Holding Group Limited in 2016 and he is the Risk and Acquisition Manager of Fameline Holding Group with vast experience in Business Consulting, Control Assurance, Internal Audits, Reorganizations of Groups of Companies, Valuations, Business Plans, Financial Due Diligence Reviews and IT Audit and Cyber Security Projects. Prior joining Fameline Holding Group, Constantinos was a Director of Risk Advisory at Deloitte where he served as a senior in charge on a number of Advisory engagements in a number of industry sectors covering Financial Services, Shipping, Wholesale & Distribution and Public Sector. Constantinos combines the knowledge gained from delivering Risk and Financial assignments with insights obtained from a wide range of IT audits and advisory projects centred around risk management, regulatory compliance, control assurance and cybersecurity.

  • no photo

    Alexis Charalambides

    Director

    Mr. Alexis Charalambides has completed his studies in economics at the University of Leicester in 1990 when he was firstly involved in the family business, Charalambides Dairies Limited. In 2008, Vivartia (Cyprus) Limited was formed from the merger of Charalambides Dairies and Christis Dairies and in 2011 Charalambides Christis Ltd was formed by the acquisition of the company by Mr. Alexis Charalambides and Mr. Menelaos Shiacolas families. Charalambides Christis is the largest and longest-running dairy industry in Cyprus. It remains a leader in the food production and distribution sector, timelessly providing, and always in accordance with international standards of quality and know-how, products of high nutritional value and quality, while preserving the authenticity of flavours. It is one of the most powerful industries in the country and is also distinguished for its Corporate Social Responsibility, with the active giving and social solidarity programme “SYMMETOCHI”, embracing the whole of Cyprus, and providing thousands of smiles to children’s faces. The quality of Charalambides Christis is internationally recognised with the company being active in more than 40 countries, making it the largest export company in Cyprus. Mr. Charalambides is the Executive Chairman of the Board of Directors of Charalambides Christis Ltd since 2011. Additionally, he is a member of the Board of Directors of the Cyprus Employers & Industrialists Federation and a member of the Industrial Committee of the Nicosia Chamber of Commerce and Industry. He is also a member of the Board of Directors of the Cyprus Institute of Neurology & Genetics and the Vice President of the Nicosia Race Club which he has served as the President in 2007 and 2008, and an elected member of the Board since 2004.

  • Georgios Kallenos

    Georgios Kallenos

    Director

    Georgios Kallenos is from Dhali, Nicosia and he is married with 3 children. He attended the Pancyprian Gymnasium of Nicosia and after the completion of his national duty he went for studies in New York, United States. He is a graduate from St. John’s University of New York where he has earned a BSc in Economics. From the same University he has earned with scholarship the Master of Business Administration (MBA). While he was studying in New York he worked in the construction market (Aluminum siding) where he eventually founded a small construction company taking sub construction contracts from bigger construction companies. At the same time he was working as a Church manager and Greek school teacher at the Greek Orthodox Church of Resurrection in Clen Cove Long Island. Georgios Kallenos has more than 25 years experience in the areas of Information Technology, Property Development and Investments. He is the founder and the Managing director of the following companies:

    G. Kallenos Infosystems Ltd which specializes in the area of customized Software applications and computer networks,
    G. Kallenos Developers Ltd specializes in the planning & development of residential and commercial building projects, and GAPILK Investments Ltd which participates in the share capitals of various innovating companies such as the NIPD Genetics.
    He has served as a member of the board of directors of the Cyprus Institute of Neurology and Genetics (CING) from 2014 – 2018.
    Georgios serves as president of the AHEPA Cyprus CY004 “Photos Photiades” Idalion chapter.

Scientific Advisors

  • no photo

    Suresh Jhanwar

    Scientific Advisor

    Prof. Suresh Jhanwar has forty years of clinical and research experience in Cancer Genomics and Molecular Medicine and he is recognized as a world renowned scientist in the field of Cancer Genetics. He served as the Director of the Cytogenetics Laboratory at the Memorial Sloan Kettering Cancer Center’s (MSKCC) from 1996 to 2013. His laboratory was the first one to be designated as the “Laboratory of Solid Tumor Genetics” in 1988, at the Department of Pathology of Memorial Sloan Kettering Cancer Center. In 2015, he was appointed as a Member Emeritus at the MSKCC. He has received many international honors and awards and he has professional certification and licensing in Cancer Cytogenetics, Molecular Oncology and Predisposition Cancer Genetics specialties, from the New York Department of Health, USA. He also served as a key member of various disease management teams and actively participated in various clinical trials for both hematologic as well as solid tumors. Prof. Jhanwar was recently elected as a Foreign Fellow of the oldest Academy of Sciences in India, which in the past 30 years elected only 84 such fellows internationally. He also served as Professor of Pathology in the Department of Pathology and Laboratory Medicine of Weill Cornell Medical College. Prof. Jhanwar also serves as a member of the editorial boards of several journals including Anticancer Research, International Journal of Human Genetics, and Cancer Genomics and Proteomics. He has published in high impact journals like PNAS, Science, Nature, Nature Genetics, NEJM, Blood, Oncogene, MCB, Cancer Research, Cell and EMBO, among others, resulting in more than 225 publications.

  • no photo

    Joris Vermeesch

    Scientific Advisor

    Prof Joris Vermeesch was born in Belgium in 1965. He obtained his BSc degree from the Bioengineer University of Gent, Belgium and his PhD degree in Chemistry and Biotechnology from the University of Nebraska, USA. He is the Head of the Cytogenetics unit of the CME-UZ research group since 2001 and the Coordinator of Genomics Core since 2008. Furthermore, as from 2008, Prof. Vermeesch has been elected as the President of the Belgian Society of Human Genetics. He also serves as member of the Board of Directors of several organizations such as the International Standards on Array CGH Consortium (ISCA), the European Cytogenetics external Quality Control and the International Society of Prenatal Diagnosis. He is the founder of a biotech spin-off company known as “Cartagenia”. Prof. Vermeesch is a scientist with international reputation in the provision of cytogenetics, genomics, genetics, single cell, preimplantation, prenatal and postnatal diagnosis. He has published more than 130 peer review papers in scientific journals including Nature, J Med Genet, Am J Hum Genet, Nucleic Acid research, etc. He has collaborated with Prof. Patsalis in several research projects in the last ten years with great success.

  • Voula-Velissariou

    Voula Velissariou

    Scientific Advisor

    Dr. Voula Velissariou received her BSc degree from the Department of Biology, University of Athens, Greece and her PhD in Genetics from the Department of Genetics, University of Cambridge, UK. She underwent specialization training in cytogenetic prenatal diagnosis methods and CVS culture techniques from the Department of Medical Genetics, Churchill Hospital, Oxford, UK. Dr Velissariou has also obtained training in molecular cytogenetic methodologies from Guy’s Hospital, London and University College London, London. Dr Velissariou is the Head of the Cytogenetics and Molecular Genetics Department in Bioatriki SA in Athens, Greece since January 2016. She has served as founder member of the Panhellenic Association of Medical Geneticists as well as member of the board of Panhellenic Union of Biologists. She is a scientist with an international reputation in the provision of prenatal and postnatal genetic diagnostic services in Greece with 30 years’ experience.

  • no photo female

    Jūratė Kasnauskienė

    Scientific Advisor

    Assoc. professor Jūratė Kasnauskiene from Lithuania joined NIPD team in 2016 for scientific and clinical collaboration. She has a MD and PhD in Clinical Genetics at Vilnius University, more than 20 years professional experience in molecular genetic testing, clinical counseling and teaching (she is assoc. professor of Vilnius University) and currently works as a Head of department of Molecular Diagnostic at Klaipeda University Hospital. Jurate is a member European and Lithuanian Society of Human Genetics as well as a board member of Lithuanian Society of Laboratory Medicine. She has participated and leaded numerous Lithuanian and European scientific and healthcare projects and has worked in committees of Lithuanian Ministry of Health. Jurate has published a number of international publications and has taken trainings in Germany, Netherlands, Taiwan, Spain, Cyprus, UK. Jurate’s fields of interest include cancer genetics and prenatal genetics as well as infertility genetics and intellectual disabilities genetics.

NIPD Genetics - Privacy Policy

General Statement

This Privacy Policy applies only to www.nipd.com and its subdomains (hereafter collectively referred to as “Sites") that link to this policy. NIPD Genetics Sites are owned by NIPD Genetics Public Company Ltd and are operated by NIPD Genetics Public Company Ltd and on occasion by a third-party that is responsible for the technical maintenance of the Sites.

If, you do not agree with this Privacy Policy, please do not access or use any of NIPD Genetics Sites.

NIPD Genetics values your interest in NIPD Genetics, its products and its services. NIPD Genetics takes the protection of your data seriously.

Personal data for purposes of this Privacy Policy, is any information by which you can be individually identified, including, but not limited to, your name, profession, address, e-mail address, and telephone number.

You may contact NIPD Genetics Public Company Ltd at
NIPD Genetics Public Company Ltd
Neas Engomis 31
Engomi, Nicosia
2409, Cyprus

NIPD Genetics Data Protection Officer can be reached at dpo@nipd.com

This Privacy Policy applies only to the Sites as defined above and which are operated by NIPD Genetics. The NIPD Genetics Privacy Policy seeks to inform the users of its Sites of the following:

NIPD Genetics will not use or share your information with anyone, except as described in this Privacy Policy. This Privacy Policy does not apply to any information we might collect by other digital and offline means and or from other digital and offline sources. The use of information collected through our Sites shall be limited to the purposes under this Privacy Policy and our Terms of Use to customers.

This page informs you of our policies regarding the collection, use, and disclosure of personal data when you use our Sites and the choices you have associated with that data.

We use your data to provide and improve the Sites. By using the Sites, you agree to the collection and use of information in accordance with this policy. Unless otherwise defined in this Privacy Policy, terms used in this Privacy Policy have the same meanings as in our Terms and Conditions, accessible from www.nipd.com

Type of personal information NIPD Genetics may collect through its Sites

Information Collection And Use

We collect several different types of information for various purposes to provide and improve our Sites and services to you.

Personal Data

While using NIPD Genetics Sites, you may be asked to provide NIPD Genetics certain personally identifiable information that can be used to contact or identify you ("Personal Information"). Personal Information that might be used to identify you includes, but is not limited to:

If you send us a query via our Contact us form, your email address, the content and any follow up emails are retained indefinitely.

Cookies and Usage Data

Usage Data

We may also collect information how the Sites are accessed and used ("Usage Data"). This Usage Data may include information such as your computer's Internet Protocol address (e.g. IP address), browser type, browser version, the pages of our Sites that you visit, the time and date of your visit, the time spent on those pages, unique device identifiers and other diagnostic data.

Tracking & Cookies Data

We use cookies and similar tracking technologies to track the activity on our Sites and hold certain information.

Cookies are files with small amount of data which may include an anonymous unique identifier. Cookies are sent to your browser from a website and stored on your device. Tracking technologies also used are beacons, tags, and scripts to collect and track information and to improve and analyze our Sites.

You can instruct your browser to refuse all cookies or to indicate when a cookie is being sent. However, if you do not accept cookies, you may not be able to use some portions of our Sites.

Examples of Cookies we use:

Session Cookies. We use Session Cookies to operate our Sites.

Preference Cookies. We use Preference Cookies to remember your preferences and various settings.

Security Cookies. We use Security Cookies for security purposes.

Visitor behavior cookies. To understand how visitors use and navigate the Sites

Keyword cookies. To understand how visitors discover the Sites.

Use of Data

www.nipd.com uses the collected data for various purposes:

Transfer of Data

Your information, including personal data, may be transferred to — and maintained on — computers located outside of your province, country or other governmental jurisdiction where the data protection laws may differ than those from your jurisdiction.

If you are located outside Cyprus and choose to provide information to us, please note that we transfer the data, including personal data, to Cyprus and process it there.

Your consent to this Privacy Policy followed by your submission of such information represents your agreement to that transfer.

www.nipd.com will take all reasonable steps necessary to ensure that your data is treated securely and in accordance with this Privacy Policy and no transfer of your personal data will take place to an organization or a country unless there are adequate controls in place including the security of your data and other personal information.

Disclosure of Data

NIPD Genetics complies with the protection of personal data regulation and will not sale or trade your personal data.

NIPD Genetics may disclose your personal data in the good faith belief that such action is necessary to:

Security of Data

The security of your data is important to us, but remember that no method of transmission over the Internet, or method of electronic storage is 100% secure. While we strive to use commercially acceptable means to protect your Personal Data, we cannot guarantee its absolute security.

Service Providers

We may employ third party companies and individuals to facilitate, maintain or operate our Sites ("Service Providers"), to provide the SItes on our behalf, to perform service-related services or to assist us in analyzing how our Sites is used.

These third parties have access to your Personal Data only to perform these tasks on our behalf and are obligated not to disclose or use it for any other purpose.

Analytics

We may use third-party Service Providers to monitor and analyze the use of our Sites.

Google Analytics

Google Analytics is a web analytics service offered by Google that tracks and reports website traffic. Google uses the data collected to track and monitor the use of our Service. This data is shared with other Google services. Google may use the collected data to contextualize and personalize the ads of its own advertising network.

You can opt-out of having made your activity on the Service available to Google Analytics by installing the Google Analytics opt-out browser add-on. The add-on prevents the Google Analytics JavaScript (ga.js, analytics.js, and dc.js) from sharing information with Google Analytics about visits activity.

For more information on the privacy practices of Google, please visit the Google Privacy & Terms web page

Access to your personal data, correction, deletion, and Opting Out

You have the right to review, update or delete any of your personal data by sending a request at NIPD Genetics Personal Data Officer pdo@nipd.com

Links to Other Sites

Our Sites may contain links to other sites that are not operated by us. If you click on a third-party link, you will be directed to that third party's site. We strongly advise you to review the Privacy Policy of every site you visit.

We have no control over and assume no responsibility for the content, privacy policies or practices of any third-party sites or services.

Children's Privacy

Our Service does not address anyone under the age of 18 ("Children").

We do not knowingly collect personally identifiable information from anyone under the age of 18. If you are a parent or guardian and you are aware that your Children has provided us with Personal Data, please contact us. If we become aware that we have collected Personal Data from children without verification of parental consent, we take steps to remove that information from our servers.

Changes to This Privacy Policy

We may update our Privacy Policy from time to time. We will notify you of any changes by posting the new Privacy Policy on this page.

We will let you know via email and/or a prominent notice on our Service, prior to the change becoming effective and update the "effective date" at the top of this Privacy Policy.

You are advised to review this Privacy Policy periodically for any changes. Changes to this Privacy Policy are effective when they are posted on this page.

Contact Us

If you have any questions about this Privacy Policy, please contact pdo@nipd.com

Ok got it!